









Markets
/
Stocks
/
nasdaq-cphi
/

China Pharma Holdings Inc

CPHI



View Detailed Chart

1.305USD

-0.015-1.14%

Close 12/24, 13:00（ET）Quotes delayed by 15 min

6.55MMarket Cap

LossP/E TTM



China Pharma Holdings Inc

1.305

-0.015-1.14%

Overview Company Financials Analysis

Overview

Company

Financials

Analysis

Intraday

30m

Today

-1.14%

5 Days

-3.62%

1 Month

-17.92%

6 Months

-24.13%

Year to Date

-43.87%

1 Year

-30.95%

View Detailed Chart

TradingKey Stock Score of China Pharma Holdings Inc

Currency: USD Updated: 2025-12-24

Key Insights

China Pharma Holdings Inc's fundamentals are relatively stable, and its growth potential is significant.Its valuation is considered fairly valued, ranking 121/158 in the Pharmaceuticals industry.Institutional ownership is very high.In the medium term, the stock price is expected to trend down.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

China Pharma Holdings Inc's Score

Industry at a Glance

Industry Ranking

121 / 158

Overall Ranking

451 / 4562

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

0.000

Target Price

0.00%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

China Pharma Holdings Inc Highlights

StrengthsRisks

China Pharma Holdings Inc is a company principally engaged in the development, manufacture and marketing of pharmaceutical products. The Company's products are for human use in connection, and with a variety of high-incidence and high-mortality diseases and medical conditions prevalent. The Company manufactures pharmaceutical products in the form of dry powder injectables, liquid injectables, tablets, capsules, and cephalosporin oral solutions. In addition, the Company is also engaged in the production of comprehensive healthcare products and protective products.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.53M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.53M.

Fairly Valued

The company’s latest PE is -1.28, at a medium 3-year percentile range.

Held by James Simons

Star Investor James Simons holds 10.62K shares of this stock.